ePrints@IIScePrints@IISc Home | About | Browse | Latest Additions | Advanced Search | Contact | Help

Limitations and potential of immunotherapy in ovarian cancer

Kumar, S and Acharya, S and Karthikeyan, M and Biswas, P and Kumari, S (2023) Limitations and potential of immunotherapy in ovarian cancer. In: Frontiers in Immunology, 14 .

Fro_Imm_14_2023.pdf - Published Version

Download (1MB) | Preview
Official URL: https://doi.org/10.3389/fimmu.2023.1292166


Ovarian cancer (OC) is the third most common gynecological cancer and alone has an emergence rate of approximately 308,069 cases worldwide (2020) with dire survival rates. To put it into perspective, the mortality rate of OC is three times higher than that of breast cancer and it is predicted to only increase significantly by 2040. The primary reasons for such a high rate are that the physical symptoms of OC are detectable only during the advanced phase of the disease when resistance to chemotherapies is high and around 80 of the patients that do indeed respond to chemotherapy initially, show a poor prognosis subsequently. This highlights a pressing need to develop new and effective therapies to tackle advanced OC to improve prognosis and patient survival. A major advance in this direction is the emergence of combination immunotherapeutic methods to boost CD8+ T cell function to tackle OC. In this perspective, we discuss our view of the current state of some of the combination immunotherapies in the treatment of advanced OC, their limitations, and potential approaches toward a safer and more effective response. Copyright © 2024 Kumar, Acharya, Karthikeyan, Biswas and Kumari.

Item Type: Journal Article
Publication: Frontiers in Immunology
Publisher: Frontiers Media SA
Additional Information: The copyright for this article belongs to author
Keywords: immune checkpoint inhibitor, Article; cancer prognosis; cancer survival; cancer therapy; CD8+ T lymphocyte; chemotherapy; clinical outcome; cytotoxicity; female; human; immune system; immunocompetent cell; immunosuppressive treatment; immunotherapy; ovary cancer; receptor cross-talk; spheroid cell; tumor microenvironment; breast tumor; immunotherapy; ovary carcinoma; ovary tumor, Breast Neoplasms; Carcinoma, Ovarian Epithelial; CD8-Positive T-Lymphocytes; Female; Humans; Immunotherapy; Ovarian Neoplasms
Department/Centre: Others
Date Deposited: 01 Mar 2024 10:29
Last Modified: 01 Mar 2024 10:29
URI: https://eprints.iisc.ac.in/id/eprint/84050

Actions (login required)

View Item View Item